Detailed price information for Keros Therapeutics Inc (KROS-Q) from The Globe and Mail including charting and trades.

Detailed price information for Keros Therapeutics Inc (KROS-Q) from The Globe and Mail including charting and trades.

is a clinical-stage biopharmaceutical company that specializes in developing and commercializing novel therapeutics for treating disorders related to dysfunctional signaling of the transforming growth ...

For the first time, researchers have discovered that the accumulation of aged and failing cells, called senescent cells, in ...

Endothelial cells are also likely to participate in activation, both by production of cellular fibronectin and via conversion of transforming growth factor (TGF)-beta from the latent to active ...

SAN DIEGO, Nov. 15, 2024 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage ...

HN01, a pivotal Phase 2/3 trial of ficerafusp alfa in 1L R/M HNSCC Completed upsized initial public offering, raising approximately $362 million in gross proceeds, with full exercise of the ...

In 2016, cancer biologist Johanna Joyce of the Memorial Sloan Kettering Cancer Center published a study in Science that ...

Each cytokine acts through its own receptor on target cells, and these receptors include members of the immunoglobulin (Ig) superfamily and tumour necrosis factor (TNF).

After hours: November 22 at 4:48 PM EST Loading Chart for KROS ...

× Zoomable Statistic: Select the range in the chart you want to zoom in on.